Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Axon is developing AADvac1 as a vaccine with the potential to halt the progression of tau pathology in Alzheimer's disease. AADvac1 is currently the most clinically-advanced tau immonotherapy in development.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 11, 2021
Lead Product(s) : COVID-19 Peptide Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axon Neuroscience Has a Promising Peptide Vaccine Against COVID-19 in Development
Details : Axon used its established peptide-based vaccine platform to produce a novel prophylactic COVID-19 vaccine, intended to treat infected patients and protect healthy individuals from infection.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
September 04, 2020
Lead Product(s) : COVID-19 Peptide Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
Details : A highly significant impact on neurodegeneration was shown on brain proteins in plasma - Neurofilament Light Chain, and CSF - Tau and p-Tau, and Diffusion Tensor Imaging.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 04, 2020
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 05, 2017
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2015
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 09, 2014
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 09, 2013
Reset All
